Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease.

Slides:

Advertisements

Similar presentations

Intermediate CAG repeats: Analysis of the Cooperative Huntington’s Observational Research Trial (COHORT) Ainhi D. Ha, MBBS 1, Christopher A. Beck, PhD.

Advertisements

Issues to be addressed Is BPSD one entity? Is BPSD part of the diagnosis of dementia? Are BPSD symptoms which cut across diagnoses? Which syndromes have.

Tetrabenazine (Xenazine ® ) Prestwick Pharmaceuticals NDA Peripheral and Central Nervous System Drugs Advisory Committee Meeting Beltsville, Maryland.

Quality of Life Assessment

Moderate-to-Severe Asthma Management

New Horizons for SMA.

Chronic HCV Infection and CKD

Systemic Lupus Erythematosus

Current Management and Future Options for Tardive Dyskinesia

Clinical Trials in IBD.

New Psoriasis Treatments

Psoriatic Arthritis.

Pharmaceutical- vs Dispensary-Sourced Cannabinoids

5 Things NPs and PAs Need to Know About Tardive Dyskinesia

Cardiogenic Shock.

Exploring the Spectrum of Excessive Daytime Sleepiness

Best Practices in Huntington Disease

Progression After Cancer Immunotherapy in Advanced NSCLC

Understanding the Many Faces of Pseudobulbar Affect

Ask the Onychomycosis Expert, Part 2

Ask the Onychomycosis Expert, Part 1

Standards of Care in Duchenne Muscular Dystrophy: A 2018 Update

Improving Acne Outcomes

Case Challenges in Chronic Migraine

Updates in Management of Atopic Dermatitis From Real Patient Cases

Advances in Dry Eye.

Before and After: Patient Cases in Onychomycosis

Treat to Target in Gout.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Treatment of Generalized Tonic-Clonic Seizures in the Modern Era

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

A Frontline Clinician's Guide to Managing Opioid-Induced Constipation

Multidisciplinary Perspectives on Interstitial Lung Diseases

Nontuberculous Mycobacterial Lung Disease

Improving Outcomes in OSA

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Gene Therapy: Past, Present, and Future

Tackling Atopic Dermatitis

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Immunotherapy for cSCC

Impactful Data in TD That Can Guide Treatment Decisions

Updates in Neurogenic Orthostatic Hypotension

New Recommendations on How to Stage Hidradenitis Suppurativa

When Is Biologic Therapy Appropriate for HS?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Guide to Atopic Dermatitis

Clinical Pearls on Hot Topics in MS

Challenging Questions in Huntington Chorea

The Burden of Psoriasis:

Patient Questions and Expert Answers in Psoriasis:

The Role of Maintenance Therapy in Multiple Myeloma

Expert Perspectives in the Recognition and Management of Lennox-Gastaut Syndrome.

Are We Making Progress in the Management of Huntington Disease?

The Psychiatrist's Role in Tardive Dyskinesia

Pregnancy in MS.

Hypovolemic Shock.

The Psychiatrist's Role in Tardive Dyskinesia

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Merging the Art and Science of Managing nOH in Clinical Practice

Foundations of Asthma.

Motor Fluctuations in PD

Presentation transcript:

Best Practices in the Clinical Management of Motor Symptoms Associated With Huntington Disease

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US

Triad of HD Symptoms

Natural History of HD

Natural History of Clinical HD

Diagnosis of HD

Assessing Motor Symptoms

UHDRS: DCL vs Q80 Diagnosis

Range of Motor Symptoms of HD

UHDRS Components: Behavior, Cognitive, and Function

UHDRS Components: Motor

Motor Symptoms Not Captured on UHDRS

Factors in the Decision to Treat Overall Motor Manifestations of HD

Initiating Treatment of Overall Motor Symptoms in HD

Nonpharmacologic Treatment of the Overall Motor Symptoms of HD

Pharmacologic Treatment of Motor Symptoms of HD Other Than Chorea

Treatment of Chorea Associated With HD

Pharmacologic Treatment of Chorea

Tetrabenazine

Deutetrabenazine

Assessing Treatment Efficacy on Motor Outcomes

Tetrabenazine and Deutetrabenazine

Treatment of Chorea in HD: Decision Making

Other Investigational Therapies